1. (+)-halofuginone
2. (+-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone
3. (+-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone Monohydrobromide
4. (-)-halofuginone
5. (-)-halofuginone Hydrobromide
6. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Hydrochloride (1:1), Rel-
7. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-((2s,3r)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Hydrobromide (1:1)
8. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Hydrobromide, Trans-(+-)-
9. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Trans-, Mono(2-hydroxypropanoate)(salt)
10. 6-chloro-7-bromo-(+)-febrifugine
11. 6-chloro-7-bromofebrifugine
12. 7-bromo-6-chloro-3,3-(3-hydroxy-2-piperidyl)acetonyl-4(3h)-quinazolinone-hydrolactate
13. 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
14. 7-bromo-6-chloro-3-(3-((2s,3r)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
15. 7-bromo-6-chloro-3-(3-((2s,3r)-3-hydroxy-2-piperidyl)-2-oxo-propyl)quinazolin-4-one Hydrobromide
16. 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
17. 7-bromo-6-chlorofebrifugine
18. Cebegine
19. Chloro-bromofebrifugine
20. Chlorobromofebrifugine
21. Halagon
22. Halocur
23. Halofuginon
24. Halofuginone Hbr
25. Halofuginone Hcl
26. Halofuginone Hydrobromide
27. Halofuginone Hydrobromide, (-)-
28. Halofuginone Hydrochloride
29. Halofuginone Lactate
30. Halofuginone Monohydrobromide
31. Halofuginone Monohydrochloride
32. Halofuginone, (+)-
33. Halofuginone, (-)-
34. Halofunginone
35. Ru 19110
36. Ru-19110
37. Ru19110
38. Stenorol
39. Trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone
1. (+)-halofuginone
2. Halocur
3. Halofuginone, (+)-
4. 6-chloro-7-bromo-(+)-febrifugine
5. 55837-20-2
6. Halofuginon
7. Halofuginona
8. Halofuginonum
9. H84e4y7hc9
10. L31mm1385e
11. (+/-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)-acetonyl)-4(3h)-quinazolinone
12. Halofuginone [inn:ban]
13. 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
14. Halofuginone ((2r,3s) And (2s,3r) Mixture)
15. Halofunginone
16. 7-bromo-6-chloro-3-{3-[(2r,3s)-3-hydroxypiperidin-2-yl]-2-oxopropyl}quinazolin-4(3h)-one
17. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-
18. 868851-54-1
19. Rel-7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3h)-one
20. Halofuginone [inn]
21. Halofuginonum [inn-latin]
22. Halofuginona [inn-spanish]
23. Unii-l31mm1385e
24. Halocurtm
25. Ht-100
26. 7-bromo-6-chloro-3-[3-[(2r,3s)-3-hydroxy-2-piperidyl]-2-oxo-propyl]quinazolin-4-one
27. Hfg
28. Nsc713205
29. Halofuginone [mi]
30. Unii-h84e4y7hc9
31. Schembl9541147
32. Chembl1199540
33. Dtxsid301339439
34. Zinc5784191
35. S8144
36. Akos022185424
37. Ccg-268823
38. Db04866
39. (+-)-trans-7-brom-6-chlor-3-(3-(3-hydroxy-2-piperidyl)acetonyl-4(3h)-chinazolinon
40. (+-)-trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidyl)acetonyl-4(3h)-quinazolinone
41. Trans-7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-4(3h)-quinazolinone
42. 4(3h4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Trans-(+/-)-
43. Halofuginone [ema Epar Veterinary]
44. Rel-7-bromo-6-chloro-3-[3-[(2r,3s)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-4(3h)-quinazolinone
45. Q4132745
46. (+/-)-trans-7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-4(3h)-quinazolinone Hydrobromide
47. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-((2r,3s)-3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Rel-
48. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Trans-
49. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Trans-(+-)-
50. 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, Trans-(+/-)-
51. 7-bromo-6-chloro-3-{3-[(2r,3s)-3-hydroxypiperidin-2-yl]-2-oxopropyl}-3,4-dihydroquinazolin-4-one
| Molecular Weight | 414.7 g/mol |
|---|---|
| Molecular Formula | C16H17BrClN3O3 |
| XLogP3 | 1.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 4 |
| Exact Mass | 413.01418 g/mol |
| Monoisotopic Mass | 413.01418 g/mol |
| Topological Polar Surface Area | 82 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 533 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of scleroderma, cancer, and restenosis.
In newborn calves:
- Prevention of diarrhoea due to diagnosed Cryptosporidium parvum infection, in farms with history of cryptosporidiosis. Administration should start in the first 24 to 48 hours of age.
- Reduction of diarrhoea due to diagnosed Cryptosporidium parvum infection. Administration should start within 24 hours after the onset of diarrhoea. In both cases, the reduction of oocysts excretion has been demonstrated.
* In newborn calves:
Prevention of diarrhoea due to diagnosed Cryptosporidium parvum in farms with history of cryptosporidiosis.
Administration should start in the first 24 to 48 hours of age.
Reduction of diarrhoea due to diagnosed Cryptosporidium parvum.
Administration should start within 24 hours after the onset of diarrhoea.
In both cases, the reduction of oocyst excretion has been demonstrated.
In new born calves:
- Prevention of diarrhoea due to diagnosed Cryptosporidium parvum, in farms with history of cryptosporidiosis,
Administration should start in the first 24 to 48 hours of age
- Reduction of diarrhoea due to diagnosed Cryptosporidium parvum.
Administration should start within 24 hours after the onset of diarrhoea.
In both cases, the reduction of oocysts excretion has been demonstrated.
Halofuginone, a fully synthetic small molecule, is a potent and selective regulator of stromal cell activation, cell migration and Collagen type I synthesis, a process that has been identified as a 'master switch' in the body's tissue repair process.
Coccidiostats
Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals. (See all compounds classified as Coccidiostats.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
Angiogenesis Inhibitors
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. (See all compounds classified as Angiogenesis Inhibitors.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
QP51AX08
QP51AX08
QP51AX08
Absorption
Readily bioavailable and rapidly absorbed following oral administration.
23.8 to 72.1 hours
Halofuginone is a potent inhibitor of collagen a1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also suppresses extracellular matrix deposition and cell proliferation. The profound antitumoral effect of halofuginone is attributed to its combined inhibition of the tumor stromal support, vascularization, invasiveness, and cell proliferation.
